Key Stats for AbbVie Stock
- Current Price: $230.01
- Target Price (Mid): ~$347
- Street Target: ~$254
- Potential Total Return: ~51%
- Annualized IRR: ~9.5% / year
- Earnings Reaction: +3.64% (April 29, 2026)
- Max Drawdown: 19.23% (April 27, 2026)
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
AbbVie Inc. (ABBV) did something acquirers rarely do on Monday. It announced a $10.9 billion all-cash takeover, and its own stock went up. Shares jumped 6.25% to close at $230.01 on June 22, the same day management agreed to spend nearly $11 billion on a company that has never sold a drug. Buyers paying a steep premium for an unapproved asset usually fall, so the rally is the story.
The target is Apogee Therapeutics (NASDAQ: APGE), a clinical-stage biotech. AbbVie is paying $135.11 per share in cash, a roughly 49% premium to Apogee’s prior close. The question for ABBV holders: did investors cheer a smart move, or overlook the risk in buying a drug that has not finished testing?
Why AbbVie Is Buying a Drug That Isn’t Approved Yet
The asset is zumilokibart, an extended half-life antibody that blocks IL-13, a protein that drives inflammation in atopic dermatitis (the most common form of eczema) and asthma. Its appeal is convenience. Market leader Dupixent must be injected every two weeks, while zumilokibart showed a durable Phase II response dosed once every three months or even twice a year.
That gap matters in an underserved market. On the call, Chief Commercial Officer Jeffrey Stewart said atopic dermatitis penetration is “about 8%, which is by far the lowest of any immunological category that we see, and it grows the fastest.” A leader exists, yet most patients go untreated, and AbbVie is betting a more convenient drug will pull them in. The deal also hands AbbVie a respiratory entry through APG273, an IL-13 and TSLP combination for asthma.
The Real Reason the Stock Went Up
The rally makes sense once you see the timing of the cost. CFO Scott Reents said the deal is “approximately $0.14 dilutive” to 2026 adjusted earnings per share and “approximately $0.46 dilutive” in 2027, with accretion only beginning in 2032. The dilution is small, and the payoff is years out, so it does little to the current earnings engine that the market actually prices.
That engine is Skyrizi and Rinvoq. The two immunology drugs have replaced nearly all the revenue lost as Humira fell to biosimilars, with Humira down 38.6% to $688 million in Q1 2026. Apogee is not a rescue. It is AbbVie using a strong balance sheet to buy a growth driver for the 2030s.
See historical and forward estimates for AbbVie stock (It’s free!) >>>
What Could Go Wrong
The risk is real, and management did not hide it. Phase III trials do not begin until the second half of 2026, with readouts in 2028 and approval targeted for early 2030. Some analysts questioned whether zumilokibart’s efficacy edge holds, since Dupixent blocks both IL-13 and IL-4 while zumilokibart targets IL-13 alone. Chief Scientific Officer Roopal Thakkar countered that the drug saturates IL-13 to 99% with strong skin-clearance data. If the convenience advantage is real but the efficacy edge is not, the drug becomes a niche option rather than the early-line leader AbbVie is paying for.
AbbVie is funding the deal with debt but expects to return to a net debt to EBITDA of 2x within two to three years, with no change to its credit rating or dividend. On valuation, ABBV trades at an NTM EV/EBITDA of 13.87x, above Amgen at 10.70x and Regeneron at 6.20x, while its forward P/E of 15.41x sits in line with the large-cap pharma group. For a company growing earnings off a re-rated base, that premium looks earned.
See how AbbVie performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $230.01
- Target Price (Mid): ~$347
- Potential Total Return: ~51%
- Annualized IRR: ~9.5% / year
See analysts’ growth forecasts and price targets for AbbVie stock (It’s free!) >>>
TIKR’s mid-case scenario values ABBV near $347 by December 2030, about 51% total return, and a 9.5% annualized return from here. The case rests on two revenue drivers: continued Skyrizi and Rinvoq share gains across new indications, and the roll-off of Skyrizi royalty costs that have weighed on margins. The margin driver is net income margin expanding toward roughly 42% as those costs normalize.
The primary risk is competitive erosion: if an oral IL-23 rival takes frontline share faster than expected, the revenue and margin assumptions compress together.
Upside: zumilokibart and the Apogee pipeline reach the “north of $10 billion” peak potential CEO Robert Michael described.
Downside: Phase III disappoints, and AbbVie has paid $11 billion for optionality that never converts.
Conclusion
The Apogee deal will not move AbbVie’s numbers for years, so watch the base business instead. The next test is Q2 2026 earnings in late July, where the number that matters is Skyrizi against its raised $21.6 billion full-year guide. A quarter holding above roughly $4.5 billion with growth near 30% confirms the engine is intact. Any sign Skyrizi’s frontline IBD share is slipping to oral competition would matter far more to the stock than anything Apogee does before 2030.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in AbbVie?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AbbVie, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
